

Amendments to the Claims:

Claims 1-71 are requested to be cancelled.

Claims 72-85 are being added.

This amendment adds, changes and/or deletes claims in this application. A detailed listing of all claims that are, or were, in the application, irrespective of whether the claim(s) remain under examination in the application, are presented. The text of all claims presently under examination is presented below in the listing of claims, and all claims are presented with an appropriate defined status identifier.

Detailed and Complete Listing of Claims:

Claims 1-71 (Cancelled).

Claim 72. (New) A compound of formula (I):




where

n is 1;

R₁ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, C₃-C₉ straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, and heterocycle;

D is selected from the group consisting of a bond, C₁-C₁₀ straight or branched chain alkylene, C₂-C₁₀ alkenylene, and C₂-C₁₀ alkynylene;

R₂ is selected from the group consisting of:




wherein for R₁ said alkyl, alkenyl, alkylene, alkenylene, alkynylene, aryl, heteroaryl, carbocycle, or heterocycle is optionally substituted with one or more substituents selected from R₃, where

R₃ is selected from the group consisting of hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl or alkynyl, aryl, heteroaryl, carbocycle, heterocycle, and CO₂R₄ where R₄ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, and C₂-C₉ straight or branched chain alkenyl;

or a pharmaceutically acceptable salt or solvate thereof.

Claim 73. (New) The compound of claim 72, wherein the compound is non-immunosuppressive.


Claim 74. (New) A compound according to claim 72, wherein R₂ is selected from the group consisting of



Claim 75. (New) A compound selected from the group consisting of (2S)-1-(phenylmethyl)sulfonyl-2-hydroxymethyl pyrrolidine, (2S)-1-(phenylmethyl)sulfonyl-2-pyrrolidinetetrazole, and compounds 1-9, 21-25, 30-38, 42-57, 59, 66-97, A, B, C, D, and E.

Claim 76. (New) A pharmaceutical composition, comprising:

- a) an effective amount of a compound having formula (II):










where


n is 1;

R₁ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, C₂-C₉ straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, and heterocycle;

D is selected from the group consisting of a bond, C₁-C₁₀ straight or branched chain alkylene, C₂-C₁₀ alkenylene, and C₂-C₁₀ alkynylene;

R₂ is selected from the group consisting of:





wherein for R₁ said alkyl, alkenyl, alkylene, alkenylene, alkynylene, aryl, heteroaryl, carbocycle, or heterocycle is optionally substituted with one or more substituents selected from R₃, where

R₃ is selected from the group consisting of hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl or alkynyl, aryl, heteroaryl, carbocycle, heterocycle, and CO₂R₄ where R₄ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, and C₂-C₉ straight or branched chain alkenyl;

or a pharmaceutically acceptable salt or solvate thereof; and


b) a pharmaceutically acceptable carrier.

Claim 77. (New) The pharmaceutical composition of claim 76, wherein the compound is selected from the group consisting of compounds 4 and 76-94.

Claim 78. (New) The pharmaceutical composition of claim 76, further comprising a neurotrophic factor different from those of formula (I).


Claim 79. (New) The pharmaceutical composition of claim 78, wherein said neurotrophic factor different from those of formula (I) is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotrophin-3, and neurotrophin-4/5.

Claim 80. (New) A composition according to claim 76, wherein R₂ is selected from the group consisting of



Claim 81. (New) A pharmaceutical composition, comprising:

- a) an effective amount of a compound having formula (I):



I

where

n is 1;

R₁ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, C₂-C₉ straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, and heterocycle;

D is selected from the group consisting of a bond, C₁-C₁₀ straight or branched chain alkylene, C₂-C₁₀ alkenylene, and C₂-C₁₀ alkynylene;

R₂ is selected from the group consisting of:

-COOH, -SO₃H, -SO₂HNR₃, -PO₂H, -PO₃(R₃)₂, -CN, -PO₃(R₃)₂, -PO(OH)(OR₃), -OR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -C(O)NHOH, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN -C(O)NHSO₂R₃, and -CONHCN;

wherein for R₁ said alkyl, alkenyl, alkylene, alkenylene, alkynylene, aryl, heteroaryl, carbocycle, or heterocycle is optionally substituted with one or more substituents selected from R₃, where

R₃ is selected from the group consisting of hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl or alkynyl, aryl, heteroaryl, carbocycle, heterocycle, and CO₂R₄ where R₄ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, and C₂-C₉ straight or branched chain alkenyl;

or a pharmaceutically acceptable salt or solvate thereof; and

b) a pharmaceutically acceptable carrier.

Claim 82. (New) The pharmaceutical composition of claim 81, wherein the compound is selected from the group consisting of (2S)-1-(phenylmethyl)sulfonyl-2-hydroxymethyl pyrrolidine and compounds 1-3 and 5-75.

Claim 83. (New) The pharmaceutical composition of claim 81, further comprising a neurotrophic factor different from those of formula (I).

Claim 84. (New) The pharmaceutical composition of claim 83, wherein said neurotrophic factor different from those of formula (I) is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotrophin-3, and neurotrophin-4/5.

Claim 85. (New) A composition according to claim 81, wherein R₂ is selected from the group consisting of -COOH, -SO₃H, -SO₂HNR₃, -PO₂H, -CN, -PO(OH)(OR₃), -C(O)NHOH, -C(O)NHSO₂R₃, and -CONHCN.